Rüdiger Autschbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rüdiger Autschbach has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
A. H. Diab
Dresden, Deutschland
1 shared publicationA. Haneya
Kiel, Deutschland
1 shared publication- Adrian Rotaru
Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
1 shared publication - Andreas Goetzenich
Faculty of Medicine, Department of Anesthesiology (G.S., A.G.), RWTH University Hospital Aachen, RWTH Aachen University, Germany
1 shared publication - Bernd Panholzer
Department for Cardiac Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany
1 shared publication - Christian Simon Bruells
Department of Anesthesia, Intensive and Emergency Medicine, Marien Kliniken, 57072 Siegen, Germany
1 shared publication
Latest Publications
- Open Access
- 1 April 2022
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 41 (2) , 403-415
Speckle tracking ultrasonography as a new tool to assess diaphragmatic function: a feasibility study
A reliable method of measuring diaphragmatic function at the bedside is still lacking. Widely used two-dimensional (2D) ultrasonographic measurements, such as diaphragm excursion, diaphragm thickness, and fractional thickening (FT) have failed to show clear correlations with diaphragmatic function. A reason for this is that 2D ultrasonographic measurements, like FT, are merely able to measure the deformation of muscular diaphragmatic tissue in the transverse direction, while longitudinal measurements in the direction of contracting muscle fibres are not possible. Speckle tracking ultrasonography, which is widely used in cardiac imaging, overcomes this disadvantage and allows observations of movement in the direction of the contracting muscle fibres, approximating muscle deformation and the deformation velocity. Several studies have evaluated speckle tracking as a promising method to assess diaphragm contractility in healthy subjects. This technical note demonstrates the feasibility of speckle tracking ultrasonography of the diaphragm in a group of 20 patients after an aortocoronary bypass graft procedure. The results presented herein suggest that speckle tracking ultrasonography is able to depict alterations in diaphragmatic function after surgery better than 2D ultrasonographic measurements.
- 1 April 2022
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 41 (2) , 403-415
Open AccessSpeckle tracking ultrasonography as a new tool to assess diaphragmatic function: a feasibility study
A reliable method of measuring diaphragmatic function at the bedside is still lacking. Widely used two-dimensional (2D) ultrasonographic measurements, such as diaphragm excursion, diaphragm thickness, and fractional thickening (FT) have failed to show clear correlations with diaphragmatic function. A reason for this is that 2D ultrasonographic measurements, like FT, are merely able to measure the deformation of muscular diaphragmatic tissue in the transverse direction, while longitudinal measurements in the direction of contracting muscle fibres are not possible. Speckle tracking ultrasonography, which is widely used in cardiac imaging, overcomes this disadvantage and allows observations of movement in the direction of the contracting muscle fibres, approximating muscle deformation and the deformation velocity. Several studies have evaluated speckle tracking as a promising method to assess diaphragm contractility in healthy subjects. This technical note demonstrates the feasibility of speckle tracking ultrasonography of the diaphragm in a group of 20 patients after an aortocoronary bypass graft procedure. The results presented herein suggest that speckle tracking ultrasonography is able to depict alterations in diaphragmatic function after surgery better than 2D ultrasonographic measurements.
- 1 January 2021
- Published by Georg Thieme Verlag KG
- Vol. 69 (S 01) , DGTHG-V35
Hemocompatibility-Related Adverse Events in a Real-World Cohort Comparing Three Different LVADs, the HeartWare, HeartMate II, and HeartMate 3: A Multicenter Observational Study
Objectives: Hemocompatibility-related adverse events (HRAEs) remain the Achilles heel of left ventricular assist device (LVAD) treatment. Previous study showed Promising results of the HeartMate 3 (HM3) device with lower HRAEs than with the HeartMate II (HMII) LVAD. This study aims to compare HRAEs and long-term outcomes between HMII, HeartWare (HVAD) and HM3 in a real-life cohort. Methods: We retrospectively analyzed all patients who received LVAD implantation between January 2014 and October 2019 in three mid-volume German centers. Long-term outcomes and HRAEs according to MONEMTUM3 trial's definitions were compared between HM3, HMII, and HVAD patients. We utilized competing risk regression to analyze survival free of HRAEs. Result: A total of 327 patients, 84% male with a median age of 65 years (HM3 [n = 73], HMII [n = 142], HVAD [n = 112]) contributed to a total person-time at risk of 7,793 months. Median follow-up was 22 months (IQR: 37). Intention to treat as destination therapy did not differ among HM3, HMII, and HVAD patients (53 vs. 47 vs. 51%, p = 0.627, respectively). Distribution of INTERMACS levels I and II was similar between HM3, HMII, and HVAD patients (25 vs. 30 vs. 33%, p = 0.305, respectively). HVAD and HMII patients had significantly decreased HRAEs free survival compared with HM3 (sub-hazard ratio [SHR]: 2.89 [95% CI: 1.52–5.49], p = 0.001 and SHR 3.07 [95% CI: 1.63–5.78], p = 0.001, respectively). Conclusion: HeartMate 3 showed the lowest HCS with significantly lower HRAEs compared with HVAD and HMII. HVAD patients had the highest pump thrombosis incidence. Distribution of bleeding events was similar between all three devices. HVAD and HMII patients had a clear increased hazard ratio for mortality because of HRAEs compared with HM3 patients. Publication Date: 19 February 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2021
- Published by Georg Thieme Verlag KG
- Vol. 69 (S 01) , DGTHG-V35
Hemocompatibility-Related Adverse Events in a Real-World Cohort Comparing Three Different LVADs, the HeartWare, HeartMate II, and HeartMate 3: A Multicenter Observational Study
Objectives: Hemocompatibility-related adverse events (HRAEs) remain the Achilles heel of left ventricular assist device (LVAD) treatment. Previous study showed Promising results of the HeartMate 3 (HM3) device with lower HRAEs than with the HeartMate II (HMII) LVAD. This study aims to compare HRAEs and long-term outcomes between HMII, HeartWare (HVAD) and HM3 in a real-life cohort. Methods: We retrospectively analyzed all patients who received LVAD implantation between January 2014 and October 2019 in three mid-volume German centers. Long-term outcomes and HRAEs according to MONEMTUM3 trial's definitions were compared between HM3, HMII, and HVAD patients. We utilized competing risk regression to analyze survival free of HRAEs. Result: A total of 327 patients, 84% male with a median age of 65 years (HM3 [n = 73], HMII [n = 142], HVAD [n = 112]) contributed to a total person-time at risk of 7,793 months. Median follow-up was 22 months (IQR: 37). Intention to treat as destination therapy did not differ among HM3, HMII, and HVAD patients (53 vs. 47 vs. 51%, p = 0.627, respectively). Distribution of INTERMACS levels I and II was similar between HM3, HMII, and HVAD patients (25 vs. 30 vs. 33%, p = 0.305, respectively). HVAD and HMII patients had significantly decreased HRAEs free survival compared with HM3 (sub-hazard ratio [SHR]: 2.89 [95% CI: 1.52–5.49], p = 0.001 and SHR 3.07 [95% CI: 1.63–5.78], p = 0.001, respectively). Conclusion: HeartMate 3 showed the lowest HCS with significantly lower HRAEs compared with HVAD and HMII. HVAD patients had the highest pump thrombosis incidence. Distribution of bleeding events was similar between all three devices. HVAD and HMII patients had a clear increased hazard ratio for mortality because of HRAEs compared with HM3 patients. Publication Date: 19 February 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany